Patent · US Active

Cytomegalovirus antigens and uses thereof

US10167321B2 · kind B2 · utility

8Cited by

1References

60Claims

0Family size

Assignee

GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

Andrea Carfi · Cambridge, US
Claudio CIFERRI · Oakland, US
Yi XING · Andover, US

Key dates

Filing date	Jan 22, 2016
Grant date	Jan 1, 2019
Priority date	—
Expiry date	Jan 22, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2710/16151
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.